一线他拉唑帕利联合恩扎卢胺对比安慰剂联合恩扎卢胺治疗转移性去势抵抗性前列腺癌:随机双盲安慰剂对照3期TALAPRO-2试验的患者报告结局
TALAPRO-2研究评估一线他拉唑帕利联合恩扎卢胺对比安慰剂联合恩扎卢胺治疗转移性去势抵抗性前列腺癌的患者报告结局。结果显示联合组总体健康状况/生活质量至确定性恶化时间延长(30.8个月 vs 25.0个月,HR 0.78),但泌尿症状恶化时间、疼痛及一般健康状况无显著差异。
要点
- 他拉唑帕利联合恩扎卢胺组总体健康状况/生活质量至确定性恶化中位时间30.8个月,长于对照组25.0个月。
- 两组总体健康状况/生活质量、症状及功能量表平均变化均无≥10分的临床意义差异。
- 泌尿症状至确定性恶化时间、疼痛至恶化时间及一般健康状况两组均无显著差异。
核心结论
- 他拉唑帕利联合恩扎卢胺较安慰剂联合恩扎卢胺延长了转移性去势抵抗性前列腺癌患者总体健康状况/生活质量的至确定性恶化时间。
- 结合临床疗效与安全性数据,这些结果可为TALAPRO-2中他拉唑帕利联合恩扎卢胺的风险-获益评估提供参考。
研究设计与样本
- TALAPRO-2为随机、双盲、安慰剂对照的3期试验,在26个国家223家医院、癌症中心和医疗中心开展。
- 入组患者为正在接受雄激素剥夺治疗、无症状或轻微症状的转移性去势抵抗性前列腺癌男性(≥18岁,日本≥20岁),ECOG体能状态0或1,且未接受过延长生命的全身治疗。
- 患者按1:1随机接受口服他拉唑帕利0.5 mg每日一次或安慰剂,联合口服恩扎卢胺160 mg每日一次。
- 患者报告结局人群包括基线及至少一次基线后患者报告结局评估的意向治疗人群患者:他拉唑帕利联合恩扎卢胺组395例,安慰剂联合恩扎卢胺组398例。
- 患者报告结局为次要终点,包括BPI-SF疼痛症状、EORTC QLQ-C30及QLQ-PR25、EQ-5D-5L等指标的变化及至恶化时间。
主要发现
- 总体健康状况/生活质量至确定性恶化中位时间:他拉唑帕利联合恩扎卢胺组30.8个月(95%CI 27.0-不可估计) vs 安慰剂联合恩扎卢胺组25.0个月(95%CI 22.9-30.7),HR 0.78(95%CI 0.62-0.99),双侧p=0.038。
- 泌尿症状至确定性恶化中位时间:他拉唑帕利联合恩扎卢胺组不可估计(95%CI 不可估计-不可估计) vs 安慰剂联合恩扎卢胺组35.9个月(95%CI 32.3-不可估计),HR 0.76(95%CI 0.54-1.06),双侧p=0.11。
- BPI-SF疼痛至恶化时间:HR 0.98(95%CI 0.69-1.40),双侧p=0.93。
- 过去24小时最严重疼痛评分组间估计平均差异为-0.1(95%CI -0.3至0.1),双侧p=0.27。
- EQ-5D-5L一般健康状况组间估计平均差异为0.0(95%CI 0.0-0.0),双侧p=0.37。
关键数值与推荐
- 总体健康状况/生活质量、症状及功能量表平均变化两组均无≥10分的临床意义差异。
- 他拉唑帕利联合恩扎卢胺组中位随访28.0个月(IQR 23.9-31.7),安慰剂联合恩扎卢胺组26.8个月(IQR 23.4-30.6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic castration-resistant prostate cancer have poor prognoses, underscoring the need for novel therapeutic strategies. First-line talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer in the phase 3 TALAPRO-2 study. We aimed to evaluate patient-reported outcomes in the all-comers cohort of TALAPRO-2, which included patients with and without alterations in homologous recombination repair (HRR) genes. METHODS: TALAPRO-2 is a randomised, double-blind, placebo-controlled, phase 3 trial conducted at 223 hospitals, cancer centres, and medical centres in 26 countries worldwide. Eligible participants were male patients aged 18 years or older (≥20 years in Japan) who were receiving ongoing androgen deprivation therapy, had asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and had not received previous life-prolonging systemic therapy for castration-resistant prostate cancer or metastatic castration-resistant prostate cancer. Patients were randomly assigned (1:1) using a centralised interactive web response system and a permuted block size of 4 to oral talazoparib 0·5 mg once daily or placebo, plus oral enzalutamide 160 mg once daily. The funder, patients, and investigators were masked to allocation of talazoparib or placebo; enzalutamide was open-label. Stratification factors were HRR gene alteration status (deficient vs non-deficient or unknown) and previous treatment with docetaxel or abiraterone, or both (yes vs no) in the castration-sensitive setting. The primary endpoint was radiographic progression-free survival by blinded independent central review and has been reported previously. Patient-reported outcomes were assessed as secondary endpoints in the patient-reported outcomes population, which comprised patients from the intention-to-treat population with a baseline patient-reported outcome assessment followed by at least one post-baseline patient-reported outcome assessment. Patient-reported outcomes included mean change from baseline in patient-reported pain symptoms (per Brief Pain Inventory-Short Form [BPI-SF]); global health status/quality of life (GHS/QoL), overall cancer and prostate cancer-specific functioning and symptoms (per European Organisation for Research and Treatment of Cancer [EORTC] Core Quality of Life Questionnaire [QLQ-C30] and Quality of Life Questionnaire-Prostate [QLQ-PR25]); and general health status (per EQ-5D-5L). Time to deterioration in patient-reported pain symptoms (per BPI-SF), and time to definitive deterioration in patient-reported GHS/QoL (per EORTC QLQ-C30) and prostate cancer-specific urinary symptoms (per EORTC-QLQ-PR25) were the other secondary endpoints. This study is registered with ClinicalTrials.gov, NCT03395197, and is ongoing. FINDINGS: Between Jan 7, 2019, and Sept 17, 2020, 805 patients were enrolled and randomly assigned to treatment irrespective of HRR gene alteration status. 395 patients assigned to talazoparib plus enzalutamide and 398 assigned to placebo plus enzalutamide were included in the patient-reported outcome population. Median follow-up was 28·0 months (IQR 23·9-31·7) for talazoparib plus enzalutamide and 26·8 months (23·4-30·6) for placebo plus enzalutamide. Time to definitive deterioration in GHS/QoL was longer with talazoparib plus enzalutamide versus placebo plus enzalutamide (median 30·8 months [95% CI 27·0-non-estimable] vs 25·0 months [22·9-30·7]; hazard ratio [HR] 0·78 [95% CI 0·62-0·99]; two-sided p=0·038). Median time to definitive deterioration in urinary symptoms was non-estimable (95% CI non-estimable-non-estimable) in the talazoparib plus enzalutamide group and was 35·9 months (95% CI 32·3-non-estimable) in the placebo plus enzalutamide group (HR 0·76 [95% CI 0·54-1·06]; two-sided p=0·11). No clinically meaningful differences (≥10 points) in mean changes from baseline were observed in GHS/QoL, symptom, and functional scales between the treatment groups. No differences were observed between the groups in time to deterioration of pain as measured by the BPI-SF (HR 0·98 [95% CI 0·69-1·40]; two-sided p=0·93), mean pain scores (estimated mean difference in value of worst pain in the past 24 h between treatment groups was -0·1 [95% CI -0·3 to 0·1]; two-sided p=0·27), or general health status as measured by the EQ-5D-5L (estimated mean difference 0·0 [95% CI 0·0-0·0]; two-sided p=0·37). INTERPRETATION: Talazoparib plus enzalutamide prolonged time to definitive deterioration in GHS/QoL versus placebo plus enzalutamide. Together with clinical efficacy and safety data, these results inform the risk-benefit assessment of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer in TALAPRO-2. FUNDING: Pfizer.
引用
- Matsubara N, Azad AA, Agarwal N, et al. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025. PMID: 40179906. doi:10.1016/S1470-2045(25)00030-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。